The National Security Commission on Emerging Biotechnology (NSCEB) has raised urgent concerns regarding the competitive position of the United States in the biotechnology sector, particularly in relation to China. Established in 2022, the NSCEB aims to develop strategies to ensure that the U.S. maintains its leadership in this critical industry. Recent discussions have highlighted the potential risks of an open-door policy for Chinese innovations and assets, suggesting that regulatory barriers may be necessary to safeguard U.S. interests.
During today’s Post-Hoc Live event, Caitlin Frazer, executive director of the NSCEB, will provide insights into the commission’s findings and its policy recommendations, which are designed to address these competitive threats. With the NSCEB’s mandate set to expire at the end of this year, the urgency for decisive action is palpable. This discussion will not only shed light on the implications for U.S. biotechnology but also explore how policy changes could reshape the industry landscape.
Open the full market picture for your next decision →
